A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Publisher： Karger

E-ISSN： 1421-9794|56|6|472-477

ISSN： 0009-3157

Source： Chemotherapy, Vol.56, Iss.6, 2010-11, pp. : 472-477

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 205-213

Karger

Access to resources Recommend Favorite

Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 5, 2010-10 ,pp. : 353-358

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 41-50

Karger

Access to resources Recommend Favorite

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)

By  

Chemotherapy, Vol. 57, Iss. 4, 2011-09 ,pp. : 357-362

Karger

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite